SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Petra Mlčochová, Steven A. Kemp, Mahesh Shanker Dhar, +256

Nature

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Bo Meng, Adam Abdullahi, Isabella A.T.M. Ferreira, +219

Nature

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

Rigel Suzuki, Daichi Yamasoba, Izumi Kimura, +74

Nature

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Akatsuki Saito, Takashi Irie, Rigel Suzuki, +53

Nature

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

Tomokazu Tamura, Jumpei Ito, Keiya Uriu, +82

Nature Communications

The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance

Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, +20

Cell Reports

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

Jumpei Ito, Rigel Suzuki, Keiya Uriu, +78

Nature Communications

Various Omicron SubvariantsGeneticsViral PathogenesisGenomicsPhylogenetic Analysis +19

SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, +14

South AmericaViral EvolutionEmerging Infectious DiseasesNew VariantPathogenesis +13

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5

Tomokazu Tamura, Daichi Yamasoba, Yoshitaka Oda, +70

Communications Biology

Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells

W. Maruyama, Kotaro Shirakawa, Hiroyuki Matsui, +7

Biochemical and Biophysical Research Communications

Cancer BiologyTumor BiologyTranscriptional RegulationCancer Cell BiologyApobec3b Expression +15